Terns Pharmaceuticals, Inc.
DelistedCIK 1831363fmd_0MKW6KJJ8BAR6WGD4PFBA6RF9KManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Dec 31, 2025, 24 periods
Latest annual · FY2022
Millions- Total revenues
- 0
- Operating income
- (110)
- Net income
- (96)
- Free cash flow
- (82)
Latest quarter · Q4 FY2025
Millions- Operating income
- (28)
- Net income
- (24)
- Free cash flow
- (19)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2020 to FY2025
- n/m
Terns Pharmaceuticals, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$110.1 million | -$101.9 million | 10-K 2026-03-30 · proof | |
| Net income | -$96.2 million | -$88.9 million | 10-K 2026-03-30 · proof | |
| Cash from operating activities | -$82.2 million | -$70 million | 10-K 2026-03-30 · proof | |
| Free cash flow | -$82.2 million | -$70.1 million | 10-K 2026-03-30 · proof | |
| Total assets | $1 billion | $363.9 million | +181.7% | 10-K 2026-03-30 · proof |
| Total liabilities | $18.6 million | $18.1 million | +2.7% | 10-K 2026-03-30 · proof |
| Cash and cash equivalents | $524.7 million | $161.4 million | +225% | 10-K 2026-03-30 · proof |
- What was Terns Pharmaceuticals, Inc.'s operating income in fiscal 2025?
- Terns Pharmaceuticals, Inc. reported operating income of -$110.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$101.9 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What was Terns Pharmaceuticals, Inc.'s net income in fiscal 2025?
- Terns Pharmaceuticals, Inc. reported net income of -$96.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$88.9 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What was Terns Pharmaceuticals, Inc.'s cash from operating activities in fiscal 2025?
- Terns Pharmaceuticals, Inc. reported cash from operating activities of -$82.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$70 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What was Terns Pharmaceuticals, Inc.'s free cash flow in fiscal 2025?
- Terns Pharmaceuticals, Inc. reported free cash flow of -$82.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$70.1 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What are Terns Pharmaceuticals, Inc.'s total assets?
- As of Dec 31, 2025, Terns Pharmaceuticals, Inc. reported total assets of $1 billion, against $363.9 million a year earlier (+181.7%). Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What are Terns Pharmaceuticals, Inc.'s total liabilities?
- As of Dec 31, 2025, Terns Pharmaceuticals, Inc. reported total liabilities of $18.6 million, against $18.1 million a year earlier (+2.7%). Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What are Terns Pharmaceuticals, Inc.'s cash and cash equivalents?
- As of Dec 31, 2025, Terns Pharmaceuticals, Inc. reported cash and cash equivalents of $524.7 million, against $161.4 million a year earlier (+225%). Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1831363&period_type=annual&limit=5"Information only, not investment advice.